CLINICAL_TRIALS trial_result · 2022-12-22

Clinical Trial Update: Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. [EARLY_Phase 1]

Early Phase 1 trial evaluating LOXL2 and TGFbeta1 signaling inhibition for idiopathic pulmonary fibrosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Hal Chapman | Conditions: Idiopathic Pulmonary Fibrosis | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2022-12-22